U.S. FDA Approves JUVMO™ (tavapadon) for Parkinson's Disease

The U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease. This approval is based on data from the Phase 3 TEMPO program, demonstrating improvements in daily functioning, increased "on" time without troublesome dyskinesia, and a favorable safety profile.